Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27911897 | 0.85 | CYP1A2 (0.42) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL934496 | 0.85 | CYP2D6 (0.46) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL28040180 | 0.84 | KIF11 (0.38) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL11258582 | 0.81 | MME (0.44) | — | |
| SCHEMBL31091500 | 0.81 | KIF11 (0.43) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL4840669 | 0.81 | KIF11 (0.43) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL2772327 | 0.78 | KIF11 (0.48) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL13250261 | 0.78 | KIF11 (0.48) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL2772329 | 0.78 | KIF11 (0.48) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL1233527 | 0.78 | KIF11 (0.42) | KIF11CYP1A2CYP2D6DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12570755-B2 | Anti-CD20 antibody and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| US-12522664-B2 | Anti-CD20 antibody and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| CN-114555594-B | Substituted azacycles as TRMP modulators | 奇华顿股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240350655-A1 | THIOL-CONJUGATION WITH UNSATURATED PHOSPHORUS(V) COMPOUNDS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2024-10-24 | — | — | US | disclosed |
| CN-117946209-A | Tumor targeting molecular probe and preparation method and application thereof | 江西中医药大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | GIVAUDAN SA (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20240124601-A1 | ANTI-CD20 ANTIBODY AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2024-04-18 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-31 | — | — | US | disclosed |
| EP-1025118-A1 | SPACER PEPTIDES AND MEMBRANES CONTAINING SAME | MERCK PATENT GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020649-A1 | SPACER PEPTIDES AND MEMBRANES CONTAINING SAME | MERCK PATENT GMBH (DE) | 1999-04-29 | — | — | WO | disclosed |
| US-5011975-A | Novel (trans 1-propenyl)disulfide derivative and process for preparing the same | NIPPON MIKTRON LIMITED (JP) | 1991-04-30 | — | — | US | disclosed |
| EP-0013261-B1 | GUAIACOL ESTERS OF ALPHA- AND BETA-MERCAPTOPROPIONYLALANINE AND ALPHA- AND BETA-MERCAPTOPROPIONYLGLYCINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1982-12-01 | — | — | EP | disclosed |
| US-4299842-A | TREATMENT OF RESPIRATORY SYSTEM DISORDERS, NUCOLYTIC AGENTS | CAVAZZA CLAUDIO | 1981-11-10 | — | — | US | disclosed |
| EP-0013261-A1 | Guaiacol esters of alpha- and beta-mercaptopropionylalanine and alpha- and beta-mercaptopropionylglycine, process for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | KIF11 3328/4885CYP1A2 1434/4885CYP2D6 1572/4885 |
| US-20240350655-A1 | THIOL-CONJUGATION WITH UNSATURATED PHOSPHORUS(V) COMPOUNDS | PTMS, PHOSPHO1, TYMP | KIF11 3789/4885CYP1A2 4809/4885CYP2D6 4170/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KIF11 4388/4885CYP1A2 4816/4885CYP2D6 4642/4885 |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | TRPM8, TRPM7, TRPM5 | KIF11 3494/4885CYP1A2 968/4885CYP2D6 2096/4885 |
| US-12570755-B2 | Anti-CD20 antibody and uses thereof | CD209, BCL9, BCR | KIF11 2895/4885CYP1A2 4089/4885CYP2D6 3970/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | KIF11 4807/4885CYP1A2 1550/4885CYP2D6 1525/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | KIF11 3692/4885CYP1A2 1702/4885CYP2D6 1935/4885 |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | AADAC, ABCG2, HDAC3 | KIF11 3317/4885CYP1A2 718/4885CYP2D6 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.